La Agencia Europea de Medicamentos (EMA) otorga la designación de medicamento huérfano al tratamiento plasmático de Kedrion para la aceruloplasminemia congénita, un trastorno genético poco frecuente del metabolismo del hierro…
A non-invasive, AI-based, wearable earpiece that continuously monitors brain activity to enable the early detection of seizure risk in real time, alerting patients and caregivers minutes before an episode occurs1…
This designation marks a significant milestone for patients and reaffirms Kedrion’s commitment to addressing unmet medical needs in rare and ultra-rare diseases , /PRNewswire/ — Kedrion announces that the European…
Reference is made to the stock exchange announcement made by Zelluna ASA (the “Company”) on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a…
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 NOVEMBER 2025 at 9.00 EET 71,498 Orion Corporation A shares converted into B…
, /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune…
, /PRNewswire/ — GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik’s team at Asan Medical Center has been published…
New addition strengthens SK Biopharmaceuticals’ radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration , /PRNewswire/ — SK Biopharmaceuticals, CO., Ltd., a biotech company…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies…
, /PRNewswire/ — Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased…